We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OYST
101
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$2.06M 0.01%
+71,428
New +$2.15M
CYPH
102
Cypherpunk Technologies Inc
CYPH
$153M
$2.04M 0.01%
97,845
– –
BLCM
103
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.85M 0.01%
249,123
– –
MTNB icon
104
Matinas BioPharma
MTNB
$2.92M
$1.62M 0.01%
41,928
-33,156
-44% -$1.27M
GLMD icon
105
Galmed Pharmaceuticals
GLMD
$4.48M
$1.03M ﹤0.01%
150
– –
AFMD
106
DELISTED
Affimed
AFMD
$923K ﹤0.01%
20,000
– –
INFI
107
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$525K ﹤0.01%
580,400
– –
MRKR icon
108
Marker Therapeutics
MRKR
$23.2M
$498K ﹤0.01%
24,051
-122,969
-84% -$2.69M
ADMS
109
DELISTED
Adamas Pharmaceuticals
ADMS
$442K ﹤0.01%
172,630
– –
GNFT
110
DELISTED
Genfit
GNFT
$156K ﹤0.01%
28,396
+1,700
+6% +$19.9K
VIRX
111
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$147K ﹤0.01%
15,905
– –
REPL icon
112
Replimune Group
REPL
$1.39B
$128K ﹤0.01%
+5,141
New +$90.9K
CTMX icon
113
CytomX Therapeutics
CTMX
$715M
– –
-20,000
Closed -$153K
IDYA icon
114
IDEAYA Biosciences
IDYA
$3.83B
– –
-126,611
Closed -$522K
NERV icon
115
Minerva Neurosciences
NERV
$231M
– –
-86,066
Closed -$4.14M
TPST icon
116
Tempest Therapeutics
TPST
$16.6M
– –
-4,274
Closed -$4.4M
URGN icon
117
UroGen Pharma
URGN
$2.29B
– –
-672,912
Closed -$12M
YARW
118
Yarrow Bioscience
YARW
$97.2M
– –
-174
Closed -$1.68M
GTHX
119
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-88,026
Closed -$970K
HARP
120
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-20,447
Closed -$2.37M
RARX
121
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-2,093,839
Closed -$101M
BDSI
122
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-1,638,334
Closed -$6.21M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2020 Portfolio in Review

As of Q2 2020, Julian Baker held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Julian Baker added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Julian Baker's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Julian Baker fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Julian Baker's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Julian Baker opened 14 new positions and closed 10 in Q2 2020.
  • Julian Baker's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.